Characteristic | Total | Responder | Nonresponder | P |
Mean age ± SD (y) | 58.0 ± 10.9 | 56.3 ± 12.8 | 58.1 ± 9.8 | 0.62 |
Mean TDR ± SD (wk) | 438 ± 342 | 295 ± 237 | 360 ± 423 | 0.08 |
Estrogen receptor status positive (n) | 45/51 | 17 | 17 | 0.69 |
Progesterone receptor status positive (n) | 37/50 | 15 | 13 | 0.66 |
Her-2/neu status positive (n) | 23/48 | 8 | 9 | 0.35 |
Hepatic tumor burden > 25% (n) | 20 | 6 | 7 | 0.68 |
Extrahepatic metastases (n) | 38/58 | 15 | 17 | 0.35 |
Radioembolization | ||||
Mean radioactivity delivered ± SD (MBq) | 1,774 ± 492 | 1,717 ± 532 | 1,809 ± 381 | 0.51 |
Toxicity grades 3 and 4 | ||||
Bilirubin (n) | 3 | 1 | 1 | 0.89 |
Transaminases (n) | 4 | 2 | 1 | 0.67 |
Mean number of prior chemotherapies ± SD | 3.1 ± 1.8 | 3.1 ± 1.6 | 3.3 ± 1.9 | 0.80 |
Taxanes (%) | 86 | 80 | 95 | 0.17 |
Anthracyclines (%) | 96 | 90 | 100 | 0.16 |
Antihormonal therapies (%) | 85 | 91 | 87 | 0.30 |
Prior local hepatic therapies (%) | 17 | 16 | 25 | 0.48 |
PET parameters | ||||
Mean SUVmax at baseline ± SD | 11.5 ± 6.0 | 11.6 ± 4.5 | 10.7 ± 7.7 | 0.65 |
SUVmax at baseline > 20 (n) | 6 | 0 | 4 | 0.04 |
Change in SUVmax (%) | 11.6 | −19.6 | −3.3 | <0.001 |
TDR = time interval between initial diagnosis and radioembolization.